Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Veracyte Inc. (VCYT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 2,295,951 | $134,841,222 | -25% | 0.88% |
| 2. | Driehaus Capital Richard Driehaus | 1,045,826 | $61,421,361 | 0.36% | |
| 3. | Point72 Asset Management Steve Cohen | 737,804 | $43,331,229 | +53% | 0.05% |
| 4. | Fisher Asset Management Ken Fisher | 700,592 | $41,145,767 | -5% | 0.01% |
| 5. | BAMCO Inc. Ron Baron | 650,686 | $38,214,789 | -1% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.33 | 60,000 | $980,094.00 | 159,761 | 2022-06-10 | Filing | |
| $35.19 | 2,000 | $70,389.20 | 2,000 | 2021-06-03 | Filing | |
| $5.32 | 2,500 | $13,288.00 | 10,000 | 2016-06-03 | Filing | |
| $5.48 | 2,500 | $13,693.25 | 7,500 | 2016-06-02 | Filing | |
| $5.46 | 2,500 | $13,641.75 | 5,000 | 2016-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $53.55 | 529 | $28,328.16 | 15,097 | 2026-06-18 | Filing | |
| $52.78 | 3,200 | $168,906.24 | 15,626 | 2026-06-18 | Filing | |
| $50.12 | 1,776 | $89,007.44 | 137,240 | 2026-06-04 | Filing | |
| $49.31 | 1,400 | $69,028.54 | 139,016 | 2026-06-04 | Filing | |
| $50.09 | 1,961 | $98,229.04 | 173,280 | 2026-06-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,486,437 | $792,058,442 | 0.01% | |
| 2. | 7,702,746 | $452,382,262 | 0.02% | |
| 3. | 5,538,404 | $325,270,469 | 0.52% | |
| 4. | 4,716,191 | $276,981,897 | 0.01% | |
| 5. | 4,698,128 | $275,953,046 | 0.01% |
News See All
Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat
Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S.
Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Veracyte, Inc. first quarter 2026 financial results webcast call. At this time, all participants are in a listen-only mode.
Veracyte, Inc. (NASDAQ:VCYT) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter 2025 Financial Results Webcast.
Does Veracyte (VCYT) Offer Both Strength and Opportunity?
Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded...
UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue
Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to buy according to Wall Street analysts. On January 12, UBS reaffirmed its Buy rating for Veracyte, Inc.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
Innovation is entering a new phase of rapid acceleration, according to ARK Invest.
Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating
TheFly reported on January 5 that Guggenheim analyst Subbu Nambi raised the price target for VCYT to $50 from $45, maintaining a Buy rating on the stock.
15 High Growth Mid-Cap Stocks to Buy
The US stock market is shifting as President Trump reinforces his “America First” agenda through subsidies and incentives aimed at boosting domestic manufacturing.
Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)
The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40.
Hedge Fund Resource Center